---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008508"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:39:03.846606+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q1 rev +42% to $203.1M, net loss $62.3M on stock comp; reaffirms FY guidance

## Summary
- Revenue $203.1M (+42% YoY); net loss $62.3M (vs. $8.7M loss) driven by $59.9M stock-based comp.
- Adjusted EBITDA flat at $12.5M; Center Margin $54.2M (26.7% of rev, down from 30.7%).
- Total clinicians 4,989 (+51% YoY), net add of 199 in Q1; two acquisitions and 41 de novo centers.
- New $350M credit facility: $200M term loan, $100M delayed draw, $50M revolver; matures 2027-2028.
- Q2 2022 guidance: rev $209-214M, Center Margin $57-61M, Adj. EBITDA $12-15M; full-year reaffirmed.

## SEC filing metadata
- accession: 0000950170-22-008508
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017022008508/0000950170-22-008508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017022008508/lfst-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008508
- JSON: https://secwatch.observer/filing/0000950170-22-008508.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.